Group 1 - The stock of Basilea Pharmaceutica Ltd. (02616) increased by over 8%, reaching HKD 8.74 with a trading volume of HKD 11.72 million [1] - Singapore's Government Investment Corporation (GIC Private Limited) increased its stake in Basilea by acquiring 80.4 million shares at an average price of HKD 7.90 per share, totaling approximately HKD 635 million, resulting in a new holding of 5.49% [1] - Basilea reported a significant decline in revenue for the first half of the year, amounting to RMB 49.45 million, a decrease of 80.54% year-on-year, while R&D expenses rose by 58.75% to RMB 105 million, leading to a loss of RMB 270 million [1] Group 2 - Basilea's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [2] - The company has developed an innovative internal ADC technology platform that enhances the release of payloads selectively targeting tumors, supporting multiple ADC products in its pipeline [2] - The platform is expected to provide ongoing momentum for the company's future development [2]

Core Viewpoint - The stock of Basilea Pharmaceutica (02616) saw a significant increase of over 25% in late trading, with a current rise of 24.43% to HKD 9.27, and a trading volume of HKD 612 million [1] Financial Performance - The company reported a revenue of RMB 49.451 million, representing a year-on-year decrease of 80.54% [1] - Research and development expenses amounted to RMB 105 million, an increase of 58.75% year-on-year [1] - The net loss for the period was RMB 270 million [1] - As of June 30, the company had cash and cash equivalents plus time deposits totaling RMB 652.8 million [1] Fundraising and Financial Strategy - The company completed a placement in July 2025, raising a net amount of approximately RMB 425.79 million [1] Product and Market Strategy - The company is preparing for negotiations regarding the inclusion of its drug, Pralsetinib, in the national medical insurance drug list, which may lead to a price adjustment [1] - If Pralsetinib is included in the national medical insurance list, the expected sales growth from 2026 onwards is anticipated to offset the short-term negative impact on revenue [1] - The company is expanding its strategic focus into non-oncology areas, revealing new dual antibodies for autoimmune and inflammatory diseases, CS2013 (BAFF/APRIL) and CS2015 (OX40L/TSLP), with plans to initiate new drug clinical trial application preparations in the second half of 2025 [1]